Today, the U.S. Department of Energy (DOE) announced that 18 million node-hours have been awarded to 45 scientific projects under the Advanced Scientific Computing Research (ASCR) Leadership Computing Challenge (ALCC) program. The projects, with applications ranging from advanced energy systems to climate change to cancer research, will use DOE supercomputers to uncover unique insights about scientific problems that would otherwise be impossible to solve using experimental approaches.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a lower-intensity therapy for acute myeloid leukemia, a new target for treating chronic myelomonocytic leukemia, real-world synthetic controls for clinical trials in rare cancers, a potential biomarker to predict endocrine therapy response in breast cancer, integrated CRISPR screens to identify novel tumor suppressors, and a deeper knowledge of the immune tumor microenvironment in melanoma-derived brain metastases.
Tumors are made up of many types of cells, both cancerous and benign. The specific complexity of the cells inside brain tumors has been a trademark of the disease, one that makes treatment extremely difficult. While scientists have long known about the variety of cells within a brain tumor, the ways these tumors grow has relied on the understanding that the cells are static, unmoving and relatively fixed.
The Mark Foundation for Cancer Research and the Bloomberg~Kimmel Institute for Cancer Immunotherapy (BKI) announced today a new $10 million commitment at The Johns Hopkins University to fund novel work and advance immunotherapy research to provide lifesaving breakthroughs to people with cancer.
Brooke Emerling from Sanford Burnham Prebys has been awarded a new grant from the National Institutes of Health (NIH) to continue her work on cellular signaling in cancer. The four-year, $2.3 million project could accelerate the development of new therapies for a range of cancers, particularly metastatic breast cancer. It also offers an answer to a longstanding mystery in cancer metabolism.
Cold Spring Harbor Laboratory (CSHL) Professor Christopher Vakoc’s team discovered in 2018 a new type of small-cell lung cancer. The cancer originates from cells known as tuft cells.
A multi-institutional study led by UNC Lineberger Comprehensive Cancer Center researchers and colleagues has found that diagnostic mammography results varied across racial and ethnic groups, with the rate of diagnostic accuracy highest in non‐Hispanic white women and lowest in Hispanic women.
Adding short-term hormone therapy and pelvic lymph node radiotherapy to standard of care prostatectomy surgical bed treatment benefits prostate cancer patients whose prostate-specific antigen (PSA) levels are rising post prostatectomy, according to an international study led by Alan Pollack, M.D.,…
A team of researchers at the University of Michigan Rogel Cancer Center were the first to generate a bona fide mouse model of a Merkel cell carcinoma, a rare and potentially aggressive form of skin cancer. The study outlining these results appeared in the Journal of Clinical Investigation.
The vaginal microbiome differentiates benign disease from endometrial cancer and can even provide insight about the specific endometrial cancer type and disease severity, according to a study by investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of…
Understanding how plants process light is key to improving crop yields. Light helps plants know when to grow and flower at the right time.
A stress protein that is overactive in many types of tumor cells also has a key role in tumor-supporting cells called fibroblasts, and may be a good target for future cancer treatments, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.
A drug currently used in just 1% of cancers has significant potential against the remaining 99%, according to a new study from UH Seidman Cancer Center and Case Western Reserve University, published in the prestigious journal Nature Cancer. Ivosidenib, or AG-120, is currently used against cancers that have a mutation in the IDH1 gene. However, study results show that Ivosidenib is also effective against unmutated, or “wild-type” IDH1. The protein coded by the IDH1 gene in cancers helps cancer cells survive in a stressful tumor environment, so any inhibitor medication that could weaken this defense mechanism is considered a promising therapy. UH and CWRU scientists discovered that under conditions present in the tumor microenvironment, drugs previously believed to be selective for the mutant enzyme have activity against the normal protein. Specifically, low glucose and magnesium levels enhance drug activity. The team has now tested Ivosidenib in mouse models of pancreatic, colorectal, o
Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7. Ruben Mesa, MD, FACP, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, presented results of the MOMENTUM phase 3 randomized study, which evaluated momelotinib against a second medication, danazol, in symptomatic and anemic MF patients previously treated with standard-of-care JAK inhibitor therapy.
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators.
Cancer patients are at a greater risk for developing diabetes, according to a new study by the Steno Diabetes Center Copenhagen, Rigshospitalet, and the University of Copenhagen.
Sylvester Comprehensive Cancer Center is making another bold move to accelerate cancer research, celebrating the groundbreaking for a 244,000-square-foot, state-of-the-art Sylvester Comprehensive Cancer Center – Transformational Cancer Research Building (TCRB).
Researchers at the University of Michigan Rogel Cancer Center have found a cell nuclear receptor activated by high fat diets and synthetic substances in unregulated athletic performance enhancers fuels the progression of precancerous pancreas lesions into pancreatic cancer.
UC San Diego researchers discover mechanism linking breast cancer and diabetes, each of which promotes development and growth of the other.
While the U.S. spends twice as much on cancer care as the average high-income country, its cancer mortality rates are only slightly better than average, according to a new analysis by researchers at Yale University and Vassar College.
Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with multiple myeloma and breast cancer. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO).
UC Davis Comprehensive Cancer Center has a new chief science officer and associate director for basic science. Xiao-Jing Wang comes from the University of Colorado Anshutz Medical Campus where she focused on skin as well as head and neck cancers
In a new study, researchers at the University of Chicago Medicine Comprehensive Cancer Center and the University of Amsterdam have brought insight into one crucial step in the anti-cancer immune response process: T cell priming.
The University of Kentucky’s Center for Cancer and Metabolism (CCM) will continue its critical mission to research the metabolism of cancer with a renewed Centers of Biomedical Research Excellence (COBRE) grant award from the National Institutes of General Medical Sciences, part of the National Institutes of Health.
The prestigious grant — totaling $11.4 million — will continue to fund UK’s CCM over the next five years.
Now, a new Yale-led study has uncovered a previously unknown process by which some NSAIDs affect the body.
The National Cancer Institute-designated Montefiore Einstein Cancer Center (MECC) has partnered with the Price Family Foundation to fund eight research teams developing novel cancer therapies and improving cancer outcomes for historically marginalized communities in the Bronx.
The risk of invasive breast cancer in men may be associated with self-reported infertility in the male partner finds a study published in the open-access journal Breast Cancer Research.
The University of Maryland Medical Center celebrates the groundbreaking of a nine-story patient care tower – the Roslyn and Leonard Stoler Center for Advanced Medicine – that will become the new home of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. The $219 million building will enable the cancer center to provide the most technologically advanced, integrated care to cancer patients throughout Maryland and the region well into the future
A study led by UC Davis Cancer Center identified a binding protein in cancer cell’s nucleus, known as CHD4, as a critical agent keeping Kaposi’s sarcoma-associated herpesvirus (KSHV) dormant and undetected by the body’s immune system. CHD4 is linked to cancer cell growth in many types of cancers.
To highlight the importance of lifesaving cancer research, National Cancer Research Month, led by the American Association for Cancer Research (AACR), is recognized during May. Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, has curated a selection of ongoing research focusing on cancer disparities which features members from the Cancer Health Equity Center of Excellence.
National Comprehensive Cancer Network’s Oncology Research Program to oversee projects from early-career investigators advancing key areas for study in cancer care and biology, such as novel combination therapy, equitable access to cellular therapies, immune cell dysfunction, liquid biomarkers, genetic ancestry, oncogenic vulnerabilities, and MAIT cell antitumor activity.
Cancer researchers at the Case Western Reserve University School of Medicine say they have successfully suppressed the growth of some solid tumors in research models by manipulating immune cells known as a macrophages.
Scientists have identified a mechanism that explains how fine air pollution particles might cause lung cancer, according to a study published today in eLife.
The Harold C. Simmons Comprehensive Cancer Center has been awarded grants from the Cancer Prevention and Research Institute of Texas (CPRIT) to increase minority participation in clinical trials, expand lung cancer screening, develop brain tumor drugs, and advance innovations in drug discovery and technology.
Researchers reveal a previously unrealized complexity in cancer development, one that raises concerns and caution about targeting an enzyme popular in oncological treatments.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.
SEATTLE — Nov. 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news.
he University of Texas at El Paso is leading new research into Hispanic cancer disparities and early cancer detection with $6.1 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT).
Ulrich G. Steidl, M.D., Ph.D., co-director of the Blood Cancer Institute and associate director of basic science at the Albert Einstein Cancer Center (AECC), has received a prestigious Outstanding Investigator Award from the National Cancer Institute (NCI).
Philanthropists Richard and Carol Dean Hertzberg have committed $2.1 million to develop and maintain the Dean-Hertzberg Breast Cancer Database System Initiative at UC San Diego Health Moores Cancer Center to support the work of Anne Wallace, MD and her collaborators at Moores Cancer Center.
Scientists studying the most common and aggressive type of brain tumour in adults have discovered a new way of analysing diseased and healthy cells from the same patient.
Memorial Sloan Kettering Cancer Center (MSK) today announced a $25 million gift from Louis V. Gerstner, Jr. to create the Louis V. Gerstner, Jr. Physician Scholars Program. Designed to support the innovative research of physician-scientists who are early in their career at MSK, the Gerstner Physician Scholars Program will advance promising scientific research and further the careers of outstanding junior faculty.
A new research study at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) turns cancer scientists into molecular detectives, searching for clues for why certain cancers are able to spread and evolve by studying tissues collected within hours of death.
The National Cancer Institute renewed the “comprehensive” designation of the UC Davis Comprehensive Cancer Center in recognition of its breadth and depth in cancer research, clinical care, cancer control and population sciences.
The University of Texas MD Anderson Cancer Center is proud to support World Cancer Research Day, Sept. 24, and its efforts to promote cancer research as a driving force behind progress in cancer prevention, early detection, treatment and survivorship.
Sanford Burnham Prebys professor Peter D. Adams, Ph.D., and Salk Institute professor Gerald Shadel, Ph.D., have been awarded a grant from the NIH’s National Institute on Aging for $13 million, funding a five-year project to explore the connection between aging and liver cancer.
New research in JNCCN finds four out of five cancer therapies tested in Phase III trials do not achieve clinically-meaningful benefit in prolonging survival, and is the first study to quantify the number of false-positive, false-negative, and true-negative trial results.
The Coriell Institute for Medical Research and Van Andel Institute (VAI) have been awarded a prestigious Specialized Programs of Research Excellence (or SPORE) grant from the National Cancer Institute (award P50CA254897). The five-year grant valued at an estimated $12.4 million will support nearly 20 scientists as they work to improve epigenetic therapies for cancer. The project is co-led by Coriell’s President and CEO Jean-Pierre Issa, MD, Van Andel Institute’s Chief Scientific Officer Peter A. Jones, PhD, DSc (hon), and Johns Hopkins University and VAI’s Stephen Baylin, MD.
The EVONANO platform allows scientists to grow virtual tumours and use artificial intelligence to automatically optimise the design of nanoparticles to treat them.